Abstract
Cathepsin S has been of increasing interest as a target of medicinal chemistry efforts given its role in modulating antigen-presentation by major histocompatibility class II (MHC II) molecules as well as its involvement in extracellular proteolytic activities. Inhibition of the cathepsin S enzyme reduces degradation of the invariant chain, a crucial chaperon which also blocks peptide-binding by MHC II molecules, thereby decreasing antigen presentation to CD4+ T-cells. Extracellular cathepsin S may also be involved in angiogenesis and initiation and/or maintenance of neuropathic pain by cleavage of the membrane-bound chemokine fractalkine (CX3CL1). Cathepsin S inhibitors have thus been suggested to hold potential as therapeutics for a variety of diseases. The initial development of cathepsin S inhibitors targeted irreversible, covalent inhibitors, but more recently the focus has been on reversible inhibitors, representing both covalent modifiers of the enzyme and, of late, noncovalent inhibitors. This review details advances in cathepsin S inhibitor design as reported in the primary literature since 2006, focusing especially on structure-activity relationships of the various covalent and noncovalent inhibitor series.
Keywords: Cathepsin S, inhibitor, antigen presentation, protease, autoimmune disease, inflammation, immunomodulator, covalent binding, noncovalent binding
Current Topics in Medicinal Chemistry
Title: Recent Advances in the Design of Cathepsin S Inhibitors
Volume: 10 Issue: 7
Author(s): John J. M. Wiener, Siquan Sun and Robin L. Thurmond
Affiliation:
Keywords: Cathepsin S, inhibitor, antigen presentation, protease, autoimmune disease, inflammation, immunomodulator, covalent binding, noncovalent binding
Abstract: Cathepsin S has been of increasing interest as a target of medicinal chemistry efforts given its role in modulating antigen-presentation by major histocompatibility class II (MHC II) molecules as well as its involvement in extracellular proteolytic activities. Inhibition of the cathepsin S enzyme reduces degradation of the invariant chain, a crucial chaperon which also blocks peptide-binding by MHC II molecules, thereby decreasing antigen presentation to CD4+ T-cells. Extracellular cathepsin S may also be involved in angiogenesis and initiation and/or maintenance of neuropathic pain by cleavage of the membrane-bound chemokine fractalkine (CX3CL1). Cathepsin S inhibitors have thus been suggested to hold potential as therapeutics for a variety of diseases. The initial development of cathepsin S inhibitors targeted irreversible, covalent inhibitors, but more recently the focus has been on reversible inhibitors, representing both covalent modifiers of the enzyme and, of late, noncovalent inhibitors. This review details advances in cathepsin S inhibitor design as reported in the primary literature since 2006, focusing especially on structure-activity relationships of the various covalent and noncovalent inhibitor series.
Export Options
About this article
Cite this article as:
J. M. Wiener John, Sun Siquan and L. Thurmond Robin, Recent Advances in the Design of Cathepsin S Inhibitors, Current Topics in Medicinal Chemistry 2010; 10 (7) . https://dx.doi.org/10.2174/156802610791113432
DOI https://dx.doi.org/10.2174/156802610791113432 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Comparative Effectiveness Systematic Review and Meta-analysis of
Drugs for the Prophylaxis of Junctional Ectopic Tachycardia
Current Cardiology Reviews Vascular Damage in Impaired Glucose Tolerance: An Unappreciated Phenomenon?
Current Pharmaceutical Design The Effect of Local Alcohol Delivery in Reducing Intimal Hyperplasia Induced by Vascular Injury and the Clinical Implications
Vascular Disease Prevention (Discontinued) Anesthetic Pharmacology and Perioperative Considerations for the End Stage Liver Disease Patient
Current Clinical Pharmacology Interaction of Anthocyanins with Drug-metabolizing and Antioxidant Enzymes
Current Medicinal Chemistry Multifaceted Individualities in Pharmacological Treatments of Obesity
Current Clinical Pharmacology Meet Our Editorial Board Member
Current Vascular Pharmacology Exploring the Cardio-metabolic Relevance of T-cadherin: A Pleiotropic Adiponectin Receptor
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Trends in the Surgical Armamentarium for Minimally Invasive Heart Valve Therapies
Recent Patents on Biomedical Engineering (Discontinued) The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets Strategies to Avoid TAVI-related Acute Kidney Injury
Current Pharmaceutical Design Perivascular Adipose Tissue, Inflammation and Vascular Dysfunction in Obesity
Current Vascular Pharmacology Toxicity of Carbon Nanotubes
Current Drug Metabolism Tools and Procedures for Ex Vivo Vein Arterialization, Preconditioning and Tissue Engineering: A Step Forward to Translation to Combat the Consequences of Vascular Graft Remodeling
Recent Patents on Cardiovascular Drug Discovery Modulation of Neutrophil Function by Hormones
Current Immunology Reviews (Discontinued) Role of C-Reactive Protein in Acute Myocardial Infarction and Stroke: Possible Therapeutic Approaches
Current Pharmaceutical Biotechnology Design of Multifunctional Polysaccharides for Biomedical Applications: A Critical Review
Current Organic Chemistry A Murine Model of Vasculitis Induced by Fungal Polysaccharide
Cardiovascular & Hematological Agents in Medicinal Chemistry Aldosterone, From (Patho)Physiology to Treatment in Cardiovascular and Renal Damage
Current Vascular Pharmacology Effects of Altered Plasminogen Activator Inhibitor-1 Expression on Cardiovascular Disease
Current Drug Targets